IMPACT trial: Predictive factors for maintenance therapy with MGN1703 in patients with metastatic colorectal carcinoma.
Jorge Riera-Knorrenschild
No relevant relationships to disclose
Werner Scheithauer
No relevant relationships to disclose
Hendrik Kröning
No relevant relationships to disclose
Frank Mayer
No relevant relationships to disclose
Dieter Nitsche
No relevant relationships to disclose
Reinhard Ziebermayr
No relevant relationships to disclose
Johannes Andel
No relevant relationships to disclose
Dirk Arnold
No relevant relationships to disclose
Burghardt Wittig
Consultant or Advisory Role - MOLOGEN
Stock Ownership - MOLOGEN
Hans-Joachim Schmoll
No relevant relationships to disclose